Disclosed are vaccine compositions comprising one or more nucleic acid encoding one or more amino acid sequence(s) selected from the group consisting of amino acid sequences of tyrosinase (Tyr), tyrosinase-related protein 1 (TYRP1 ), tyrosinase-related protein 2 (TYRP2), melanoma-associated antigen 4 protein (MAGEA4), growth hormone release hormone (GHRH), MART-1/melan-A antigen, cancer testis antigen NY-ESO-1, cancer testis antigen NY-ESO-2, preferentially expressed antigen in melanoma (PRAME), Wilms' tumor 1 (WT1), and human telomerase reverse transcriptase (hTERT). The vaccine compositions can further comprise a nucleic acid encoding one or more other antigens including prostate specific antigen (PSA). Further disclosed are methods of preventing or treating cancer in a subject in need comprising administering to the subject a vaccine composition comprising a particular number of cancer antigens for treating or preventing a particular cancer.
